H3N2 Infection - Pipeline Review, H2 2015

H3N2 Infection - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘H3N2 Infection - Pipeline Review, H2 2015’, provides an overview of the H3N2 Infection’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for H3N2 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H3N2 Infection and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of H3N2 Infection
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for H3N2 Infection and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the H3N2 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the H3N2 Infection pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for H3N2 Infection
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding H3N2 Infection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
H3N2 Infection Overview
Therapeutics Development
Pipeline Products for H3N2 Infection - Overview
Pipeline Products for H3N2 Infection - Comparative Analysis
H3N2 Infection - Therapeutics under Development by Companies
H3N2 Infection - Therapeutics under Investigation by Universities/Institutes
H3N2 Infection - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
H3N2 Infection - Products under Development by Companies
H3N2 Infection - Products under Investigation by Universities/Institutes
H3N2 Infection - Companies Involved in Therapeutics Development
Aphios Corporation
Crucell N.V.
CSL Limited
ILiAD Biotechnologies, LLC
Inovio Pharmaceuticals, Inc.
Johnson & Johnson
Medicago Inc.
Mucosis B.V.
NanoViricides, Inc.
REPLICor Inc.
Sarepta Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
H3N2 Infection - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
APP-0205 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
APP-309 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aspidasept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-9114 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gamma-Flu - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ID-38 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strain A/H3N2] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza [Strains H1N1, H3N2, influenza B] (quadrivalent) virus like particle vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
influenza vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-872 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for Influenza A Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVINF-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVINF-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pertussis [strain BPZE1] vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PNSIA-28 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
radavirsen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REP-9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for RSV and Influenza A Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
H3N2 Infection - Recent Pipeline Updates
H3N2 Infection - Dormant Projects
H3N2 Infection - Product Development Milestones
Featured News & Press Releases
Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100
Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza
Jul 26, 2012: Novartis Begins Shipment Of Fluvirin Seasonal Influenza Vaccine In US For 2012-2013 Influenza Season
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for H3N2 Infection, H2 2015
Number of Products under Development for H3N2 Infection - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
H3N2 Infection - Pipeline by Aphios Corporation, H2 2015
H3N2 Infection - Pipeline by Crucell N.V., H2 2015
H3N2 Infection - Pipeline by CSL Limited, H2 2015
H3N2 Infection - Pipeline by ILiAD Biotechnologies, LLC, H2 2015
H3N2 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015
H3N2 Infection - Pipeline by Johnson & Johnson, H2 2015
H3N2 Infection - Pipeline by Medicago Inc., H2 2015
H3N2 Infection - Pipeline by Mucosis B.V., H2 2015
H3N2 Infection - Pipeline by NanoViricides, Inc., H2 2015
H3N2 Infection - Pipeline by REPLICor Inc., H2 2015
H3N2 Infection - Pipeline by Sarepta Therapeutics, Inc., H2 2015
H3N2 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
H3N2 Infection Therapeutics - Recent Pipeline Updates, H2 2015
H3N2 Infection - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for H3N2 Infection, H2 2015
Number of Products under Development for H3N2 Infection - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook